Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

GSK and J&J back $1 billion biotech spin-off from Index Ventures

Published 02/02/2016, 06:28
Updated 02/02/2016, 06:28
© Reuters. The signage for the GlaxoSmithKline building is pictured in London

© Reuters. The signage for the GlaxoSmithKline building is pictured in London

By Ben Hirschler

LONDON (Reuters) - Index Ventures, an early investor in technology hits like Skype and Dropbox, is spinning off its biotech portfolio into a new $1 billion (695 million pounds) business, with backing from drug giants GlaxoSmithKline (L:GSK) and Johnson & Johnson (N:JNJ).

The new Medicxi Ventures business will be led by the existing life sciences team from Index Ventures and includes all the current biotech portfolio companies.

Medicxi said on Tuesday it had raised 210 million euros ($229 million) for a new fund focused on early-stage life sciences investments in Europe, with GSK and J&J each contributing 25 percent.

That takes funds under management at Medicxi to around $1 billion, making it one of the largest independent European life sciences-focused investment firms.

"We are doubling down on life sciences and early-stage investments across Europe," said general partner Francesco De Rubertis, who expects 80 to 90 percent of Medicxi investments to be in Europe.

Although Europe plays second fiddle to the United States when it comes to developing successful biotech companies, the continent's universities carry out much of the cutting-edge science behind new medicines.

"Every year, around 30 to 40 percent of the drugs approved by the FDA (U.S. Food and Drug Administration) were actually discovered in European academic labs," De Rubertis said.

The new financing marks a further vote of confidence by GSK and J&J in Index's so-called asset-centric approach to biotech investing. Both pharmaceutical companies first linked with Index in a European biotech fund round in 2012.

In contrast to the traditional idea of building fully integrated new businesses, Index invests in "virtual" companies with a single experimental medicine and minimal infrastructure.

Last year, for example, it sold XO1, a British firm working on an early-stage anti-blood clotting drug with just two employees.

That approach is increasingly at odds with the conventional tech approach to building a company.

Index Ventures is best known for its investments in tech businesses but the company has also backed a number of successful biotech firms, including Denmark's Genmab (CO:GEN).

The life sciences operations being carved out to form Medicxi account for about a third of Index's investments. The Index Ventures technology practice remains unchanged.

De Rubertis will manage Medicxi along with three other ex-Index general partners - David Grainger, Kevin Johnson and Michele Ollier.

© Reuters. The signage for the GlaxoSmithKline building is pictured in London

($1 = 0.9175 euros)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.